NANO MRNA Co.,Ltd. (TYO:4571)

Market Cap	9.74B
Revenue (ttm)	108.00M
Net Income (ttm)	-835.00M
Shares Out	70.60M
EPS (ttm)	-11.84
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	183,300
Average Volume	672,515
Open	138.00
Previous Close	136.00
Day's Range	136.00 - 139.00
52-Week Range	113.00 - 230.00
Beta	0.14
RSI	48.85
Earnings Date	Aug 8, 2025

About NANO MRNA

NANO MRNA Co.,Ltd. researches, develops, produces, and sells pharmaceuticals using micellar nanoparticles technology in Japan. The company’s pipeline products include RUNX1 (mRNA) for the treatment in the area of tissue generation and vaccines; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer. Its product pipeline also comprises TUG1 (ASO) for glioblastoma multiforme. In addition, it offers Complex, an antibacterial ear drops; cosmetic raw material, and platelet-rich therapy. The company was for...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 20
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4571

Financial Performance

In 2024, NANO MRNA's revenue was 108.00 million, a decrease of -20.00% compared to the previous year's 135.00 million. Losses were -835.00 million, 7.05% more than in 2023.